Not admitted · Not a forecast
Rules 1.1.0 · as of 14 Sep 2026
Owen Scott Muir · Said 12 Jun 2023 · owen-0535
Quote
Not a forecast
“It is worth noting they're wildly expensive, and could account for $736,000,000,000 if we just treated half of people with obesity with the existing semeglutide at the existing market price.”
Personal essay on GLP-1 drugs (Ozempic/semaglutide, then Mounjaro/tirzepatide) for metabolic syndrome. Conditional cost estimate: treating half of people with obesity with semaglutide at the current market price would cost $736 billion.
Descriptive, retrospective, or a statement of preference; no future state asserted.